SABS
HEALTHCARESAB Biotherapeutics Inc
$3.80+0.12 (+3.26%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SABS Today?
No stock-specific AI insight has been generated for SABS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.60$5.15
$3.80
Fundamentals
Market Cap$267M
P/E Ratio—
EPS$-0.79
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin—
Debt / Equity—
Trading
Volume711K
Avg Volume (10D)—
Shares Outstanding70.3M
SABS News
20 articles- SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ETYahoo Finance·May 5, 2026
- Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142Yahoo Finance·Apr 29, 2026
- SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026Yahoo Finance·Apr 22, 2026
- SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society CongressYahoo Finance·Apr 15, 2026
- SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Mar 19, 2026
- SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Mar 18, 2026
- SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Mar 17, 2026
- SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 DiabetesYahoo Finance·Mar 10, 2026
- SAB BIO Reports Full Year 2025 Financial Results and Business HighlightsYahoo Finance·Mar 9, 2026
- SAB BIO to Participate in Upcoming Investor ConferencesYahoo Finance·Mar 2, 2026
- SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer ConfMarketbeat·Mar 1, 2026
- SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026Marketbeat·Feb 15, 2026
- Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny StocksYahoo Finance·Jan 25, 2026
- SAB BIO Strengthens Board of Directors with Appointment of New Chair and New DirectorYahoo Finance·Jan 7, 2026
- SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 6, 2026
- First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1DYahoo Finance·Dec 18, 2025
- SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1DYahoo Finance·Dec 17, 2025
- SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes ManagementYahoo Finance·Dec 8, 2025
- SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners are individual investors who got richer after stock soared 22% last weekYahoo Finance·Nov 22, 2025
- SAB BIO Reports Third Quarter Financial Results and Recent Business HighlightsYahoo Finance·Nov 13, 2025
All 20 articles loaded
Price Data
Open$3.80
Previous Close$3.68
Day High$3.98
Day Low$3.63
52 Week High$5.15
52 Week Low$1.60
52-Week Range
$1.60$5.15
$3.80
Fundamentals
Market Cap$267M
P/E Ratio—
EPS$-0.79
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin—
Debt / Equity—
Trading
Volume711K
Avg Volume (10D)—
Shares Outstanding70.3M
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—